Aluminium in Brain Tissue in Multiple Sclerosis

Multiple sclerosis (MS) is a devastating and debilitating neurodegenerative disease of unknown cause. A consensus suggests the involvement of both genetic and environmental factors of which the latter may involve human exposure to aluminium. There are no data on the content and distribution of aluminium in human brain tissue in MS. The aluminium content of brain tissue from 14 donors with a diagnosis of MS was determined by transversely heated graphite furnace atomic absorption spectrometry. The location of aluminium in the brain tissue of two donors was investigated by aluminium-specific fluorescence microscopy. The aluminium content of brain tissue in MS was universally high with many tissues bearing concentrations in excess of 10 μg/g dry wt. (10 ppm) and some exceeding 50 ppm. There were no statistically significant relationships between brain lobes, donor age or donor gender. Aluminium-specific fluorescence successfully identified aluminium in brain tissue in both intracellular and extracellular locations. The association of aluminium with corpora amylacea suggests a role for aluminium in neurodegeneration in MS.

[1]  A. King,et al.  Aluminium in brain tissue in autism. , 2018, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[2]  C. Linhart,et al.  Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis , 2017, EBioMedicine.

[3]  A. Thompson,et al.  Challenge of progressive multiple sclerosis therapy , 2017, Current opinion in neurology.

[4]  Jeffrey A. Cohen,et al.  Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function , 2017, The Lancet.

[5]  C. Troakes,et al.  Aluminium in brain tissue in familial Alzheimer's disease. , 2017, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[6]  C. Pelegrí,et al.  New perspectives on corpora amylacea in the human brain , 2017, Scientific Reports.

[7]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[8]  C. Troakes,et al.  The Identification of Aluminum in Human Brain Tissue Using Lumogallion and Fluorescence Microscopy , 2016, Journal of Alzheimer's disease : JAD.

[9]  P. Siesjö,et al.  Unequivocal identification of intracellular aluminium adjuvant in a monocytic THP-1 cell line , 2014, Scientific Reports.

[10]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[11]  C. Exley,et al.  Elevated brain aluminium and early onset Alzheimer’s disease in an individual occupationally exposed to aluminium: a case report , 2014, Journal of Medical Case Reports.

[12]  C. Exley,et al.  Human exposure to aluminium. , 2013, Environmental science. Processes & impacts.

[13]  M. Esiri,et al.  Aluminium, iron and copper in human brain tissues donated to the Medical Research Council's Cognitive Function and Ageing Study. , 2012, Metallomics : integrated biometal science.

[14]  C. Exley,et al.  Aluminium in the human brain , 2011 .

[15]  C. Exley,et al.  Elevated urinary excretion of aluminium and iron in multiple sclerosis , 2006, Multiple sclerosis.

[16]  M. Esiri,et al.  Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  M. Golub,et al.  Morphometric studies of myelination in the spinal cord of mice exposed developmentally to aluminum. , 1999, Neurotoxicology.

[18]  M. Golub,et al.  Myelin is a preferential target of aluminum-mediated oxidative damage. , 1997, Archives of biochemistry and biophysics.

[19]  K. Selmaj,et al.  Corpora amylacea from multiple sclerosis brain tissue consists of aggregated neuronal cells. , 2008, Acta biochimica Polonica.